Zacks Investment Research on MSN
BAYRY reports positive data on kidney drug in non-diabetic CKD
Bayer BAYRY announced that finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone ...
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results